Bausch Health's (BHC) Q4 results on Feb. 19 will be mainly eyed by investors for the company's 2025 guidance, a potential full separation of Bausch + Lomb (BLCO), and upcoming debt maturities in Q4 this year, RBC Capital Markets said Thursday.
RBC said it expects Bausch Health to post Q4 revenue of $2.56 billion, above the FactSet consensus of $2.52 billion, and adjusted EBITDA of $918.8 million, below the FactSet consensus of $939 million.
For 2025, RBC expects Bausch Health to deliver revenue of $10.01 billion, above consensus at $9.9 billion, and adjusted EBITDA of $3.42 billion, in line with consensus forecasts.
Meanwhile, the investment firm said it trimmed Bausch Health's price target to $10 from $11 as it's decreasing the Bausch + Lomb sale scenario weighting to 60% from 75% after a media report saying that Blackstone (BX) will likely drop out of a consortium with TPG (TPG) to take out the eye care company.
A potential sale of Bausch + Lomb would result in about $6.5 billion to $7.7 billion in proceeds to Bausch Health, RBC said.
The investment firm has a sector perform rating on Bausch Health.
Price: 7.46, Change: -0.01, Percent Change: -0.19
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。